GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pakistan Ltd (KAR:GLAXO) » Definitions » Cyclically Adjusted PS Ratio

GlaxoSmithKline Pakistan (KAR:GLAXO) Cyclically Adjusted PS Ratio : 3.31 (As of Apr. 22, 2025)


View and export this data going back to 1953. Start your Free Trial

What is GlaxoSmithKline Pakistan Cyclically Adjusted PS Ratio?

As of today (2025-04-22), GlaxoSmithKline Pakistan's current share price is ₨457.37. GlaxoSmithKline Pakistan's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was ₨138.34. GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio for today is 3.31.

The historical rank and industry rank for GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio or its related term are showing as below:

KAR:GLAXO' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.58   Med: 1.06   Max: 3.22
Current: 3.18

During the past years, GlaxoSmithKline Pakistan's highest Cyclically Adjusted PS Ratio was 3.22. The lowest was 0.58. And the median was 1.06.

KAR:GLAXO's Cyclically Adjusted PS Ratio is ranked worse than
66.35% of 731 companies
in the Drug Manufacturers industry
Industry Median: 1.99 vs KAR:GLAXO: 3.18

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

GlaxoSmithKline Pakistan's adjusted revenue per share data for the three months ended in Dec. 2024 was ₨55.220. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₨138.34 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


GlaxoSmithKline Pakistan Cyclically Adjusted PS Ratio Historical Data

The historical data trend for GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pakistan Cyclically Adjusted PS Ratio Chart

GlaxoSmithKline Pakistan Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.30 0.76 0.66 2.87

GlaxoSmithKline Pakistan Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.65 1.09 1.42 2.87

Competitive Comparison of GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio falls into.


;
;

GlaxoSmithKline Pakistan Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=457.37/138.34
=3.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pakistan's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, GlaxoSmithKline Pakistan's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=55.22/133.1571*133.1571
=55.220

Current CPI (Dec. 2024) = 133.1571.

GlaxoSmithKline Pakistan Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 18.002 99.621 24.062
201506 18.647 100.684 24.661
201509 18.252 100.392 24.209
201512 19.849 99.792 26.485
201603 19.193 100.470 25.437
201606 21.498 101.688 28.151
201609 21.766 101.861 28.453
201612 24.223 101.863 31.665
201703 26.342 102.862 34.100
201706 24.594 103.349 31.687
201709 24.077 104.136 30.787
201712 27.918 104.011 35.741
201803 28.645 105.290 36.227
201806 25.343 106.317 31.741
201809 25.293 106.507 31.622
201812 27.421 105.998 34.447
201903 26.276 107.251 32.623
201906 29.078 108.070 35.828
201909 25.653 108.329 31.532
201912 33.777 108.420 41.484
202003 25.227 108.902 30.846
202006 24.319 108.767 29.772
202009 33.990 109.815 41.215
202012 26.706 109.897 32.358
202103 24.158 111.754 28.785
202106 28.443 114.631 33.040
202109 30.827 115.734 35.468
202112 31.664 117.630 35.844
202203 27.086 121.301 29.733
202206 29.963 125.017 31.914
202209 37.703 125.227 40.091
202212 36.888 125.222 39.226
202303 35.794 127.348 37.427
202306 37.242 128.729 38.523
202309 43.409 129.860 44.511
202312 39.663 129.419 40.808
202403 49.035 131.776 49.549
202406 41.621 132.554 41.810
202409 46.246 133.029 46.291
202412 55.220 133.157 55.220

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GlaxoSmithKline Pakistan  (KAR:GLAXO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


GlaxoSmithKline Pakistan Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GlaxoSmithKline Pakistan Business Description

Traded in Other Exchanges
N/A
Address
35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company derives maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Pakistan Headlines

No Headlines